theravia

Company snapshot

theravia is a leading international pharmaceutical company focused on rare and neglected diseases. Established through the merger of Addmedica and CTRS, we are committed to tackling the unmet medical needs of patients facing these difficult conditions. For more information, please visit our website: https://theravia.com

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for theravia. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for theravia.

1. Jun 8, 2026 Clinical update

   SIKLOS PAEDIATRIC 50mg dispersible tablets — Phase 2

View all clinical trial activity →

• What is theravia?

  THERAVIA is a pharma organization headquartered in EU. Primary therapeutic focus areas include Sickle Cell Disease. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pi

• Is theravia publicly traded?

  theravia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does theravia develop or market?

  We link 4 drug profile(s) where theravia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/theravia-eu#company-drugs.

• What are the latest developments for theravia?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does theravia focus on?

  theravia focuses on Sickle Cell Disease based on our analysis of their pipeline programs and drug development activities.